
Imruza50 mg
Beacon Pharmaceuticals PLC
Azathioprine is an immunosuppressive antimetabolite with the following evidence-based uses: Established / FDA-approved indications Prevention of kidney (renal) transplant rejection - used and more.
Azathioprine is an immunosuppressive antimetabolite with the following evidence-based uses:
Use of Azathioprine for any indication should be directed and monitored by a physician experienced in immunosuppressive therapy.
Dosing of Azathioprine is individualized per indication, body weight, and clinical/laboratory response, and must be supervised by a physician experienced in immunosuppressive therapy.
| Indication | Adult Dose |
|---|---|
| Kidney transplant rejection prophylaxis | Initial dose up to 3-5 mg/kg/day, usually started at or shortly before transplantation; maintenance dose typically 1-3 mg/kg/day, adjusted to the lowest effective dose based on clinical response and blood counts. |
| Rheumatoid arthritis | Initial dose approximately 1 mg/kg/day (about 50-100 mg) given as a single dose or in two divided doses. If response is insufficient after 6-8 weeks, the dose may be increased by 0.5 mg/kg/day at 4-week intervals, up to a maximum of about 2.5 mg/kg/day. A therapeutic trial of at least 12 weeks is generally required before concluding a lack of benefit. |
| Inflammatory bowel disease / autoimmune hepatitis (guideline-supported use) | Typically 1-2.5 mg/kg/day, individualized, often combined with corticosteroids as a steroid-sparing maintenance strategy. |
Lower doses are recommended in patients with reduced kidney function (including oliguric transplant recipients), as drug clearance may be delayed; dose should be adjusted based on close monitoring of blood counts and clinical response.
Use with caution and closer monitoring, as Azathioprine and its metabolites are hepatically processed; dose reduction may be required in significant hepatic impairment.
Baseline and periodic monitoring of complete blood count (CBC) and liver function tests is required throughout treatment (see Precautions and Warnings).
Side effects of Azathioprine are generally dose-related and reversible with dose reduction or discontinuation, but some are serious.
Patients should seek urgent medical attention for fever, unusual bruising/bleeding, signs of infection, jaundice, or severe abdominal pain while taking Azathioprine.
Azathioprine is absolutely contraindicated in:
Patients previously treated with alkylating agents (e.g., cyclophosphamide, melphalan, chlorambucil) are at substantially increased risk of malignancy if given Azathioprine, and combination should be avoided unless no alternative exists and the decision is made by a specialist (see Precautions and Warnings for additional cautions such as myelosuppression risk and use in pregnancy for other indications).
Disclaimer
The information provided is accurate to the best of our knowledge, but it does not replace professional medical advice. We cannot guarantee its completeness or accuracy, and the absence of specific information about a drug should not be taken as an endorsement. We are not responsible for any consequences arising from this information, so please consult a healthcare professional for any concerns or questions.